{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Schizophrenia+Spectrum+and+Other+Psychotic+Disorders&page=57",
    "query": {
      "condition": "Schizophrenia Spectrum and Other Psychotic Disorders",
      "page": 57
    },
    "page_size": 10
  },
  "pagination": {
    "page": 57,
    "page_size": 10,
    "total_count": 1652,
    "total_pages": 166,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Schizophrenia+Spectrum+and+Other+Psychotic+Disorders&page=58&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Schizophrenia+Spectrum+and+Other+Psychotic+Disorders&page=56&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T21:53:21.477Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00980252",
      "title": "Medication Adherence in Schizophrenia: Development of a CBT-Based Intervention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Psychotic Disorders"
      ],
      "interventions": [
        {
          "name": "Cognitive Behavioral Therapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "16 Years to 45 Years"
      },
      "enrollment_count": 34,
      "start_date": "2009-11",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2014-06-16",
      "last_synced_at": "2026-10-23T21:53:21.477Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00980252"
    },
    {
      "nct_id": "NCT05268809",
      "title": "Can Neural Network Instability in Schizophrenia be Improved With a Very Low Carbohydrate Ketogenic Diet?",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Ketogenic diet",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Northern California Institute of Research and Education",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 71,
      "start_date": "2022-04-21",
      "completion_date": "2025-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-10-23T21:53:21.477Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05268809"
    },
    {
      "nct_id": "NCT02716584",
      "title": "Benefits of Physical Exercise in Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Physical exercise",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Stretching exercise",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "40 Years to 65 Years"
      },
      "enrollment_count": 53,
      "start_date": "2016-09-01",
      "completion_date": "2018-07-12",
      "has_results": true,
      "last_update_posted_date": "2019-09-19",
      "last_synced_at": "2026-10-23T21:53:21.477Z",
      "location_count": 1,
      "location_summary": "West Los Angeles, California",
      "locations": [
        {
          "city": "West Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02716584"
    },
    {
      "nct_id": "NCT02237235",
      "title": "Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "MMFS-202-302",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 60,
      "start_date": "2014-08",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2025-06-22",
      "last_synced_at": "2026-10-23T21:53:21.477Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02237235"
    },
    {
      "nct_id": "NCT00288340",
      "title": "Quantifying Abnormalities in Cortical Activation Associated With Auditory Hallucinations Using Functional Magnetic Resonance Imaging",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Hallucinations"
      ],
      "interventions": [
        {
          "name": "functional magnetic resonance imaging",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2006-01",
      "completion_date": "2006-08",
      "has_results": false,
      "last_update_posted_date": "2017-04-19",
      "last_synced_at": "2026-10-23T21:53:21.477Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00288340"
    },
    {
      "nct_id": "NCT07105098",
      "title": "NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "NBI-1117568",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 284,
      "start_date": "2025-08-11",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-23T21:53:21.477Z",
      "location_count": 7,
      "location_summary": "Little Rock, Arkansas • Culver City, California • Garden Grove, California + 4 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07105098"
    },
    {
      "nct_id": "NCT01192867",
      "title": "A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "RO4917838",
          "type": "DRUG"
        },
        {
          "name": "Antipshychotics (Standard of Care)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 629,
      "start_date": "2010-12-11",
      "completion_date": "2014-05-26",
      "has_results": false,
      "last_update_posted_date": "2017-06-26",
      "last_synced_at": "2026-10-23T21:53:21.477Z",
      "location_count": 27,
      "location_summary": "Little Rock, Arkansas • Anaheim, California • Cerritos, California + 23 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "La Palma",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01192867"
    },
    {
      "nct_id": "NCT01086748",
      "title": "A Comparator Study of LY2140023 Versus Placebo in Schizophrenia Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Risperidone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "LY2140023",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Denovo Biopharma LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1134,
      "start_date": "2010-03",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-23T21:53:21.477Z",
      "location_count": 19,
      "location_summary": "Escondido, California • Garden Grove, California • Paramount, California + 16 more",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Paramount",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01086748"
    },
    {
      "nct_id": "NCT00338598",
      "title": "Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcoholism",
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Glycine",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "21 Years to 60 Years"
      },
      "enrollment_count": 20,
      "start_date": "2003-06",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2018-01-17",
      "last_synced_at": "2026-10-23T21:53:21.477Z",
      "location_count": 1,
      "location_summary": "West Haven, Connecticut",
      "locations": [
        {
          "city": "West Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00338598"
    },
    {
      "nct_id": "NCT02901587",
      "title": "Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "Lu AF35700 (10 mg/day)",
          "type": "DRUG"
        },
        {
          "name": "Lu AF35700 (30 mg/day)",
          "type": "DRUG"
        },
        {
          "name": "Quetiapine (Seroquel XR® 800 mg/day)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lundbeck A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "21 Years to 60 Years"
      },
      "enrollment_count": 119,
      "start_date": "2016-09",
      "completion_date": "2018-04-18",
      "has_results": false,
      "last_update_posted_date": "2019-09-12",
      "last_synced_at": "2026-10-23T21:53:21.477Z",
      "location_count": 1,
      "location_summary": "Long Beach, California",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02901587"
    }
  ]
}